DEA Targets Dentist James Orrington in Drug Order Decision
Published Date: 10/20/2025
Notice
Summary
Dr. James Orrington, a dentist in Chicago, lost his DEA license to handle controlled substances because he no longer has permission to do so in Illinois. He didn’t respond to the government’s attempts to contact him, so the DEA canceled his registration. This means he can’t legally prescribe or manage certain drugs anymore, effective immediately.
Analyzed Economic Effects
4 provisions identified: 1 benefits, 3 costs, 0 mixed.
DEA Registration Revoked for Dentist
The Drug Enforcement Administration revoked James Orrington II's DEA Certificate of Registration No. BO7484811. Because his Illinois dental and controlled-substance licenses were suspended on May 23, 2024, he is not authorized to handle controlled substances in Illinois, and the revocation is effective November 19, 2025.
Pending Registration Applications Denied
The DEA denied any pending applications by James Orrington II to renew or modify his DEA registration and denied any other pending application of his for additional registration in Illinois. Those denials accompany the revocation and are effective November 19, 2025.
State License Required for DEA Registration
The Order reiterates that under federal law (21 U.S.C. 823(g)(1) and 824(a)(3)) a practitioner must be authorized by the State in which they practice to dispense controlled substances in order to hold a DEA registration. If a practitioner's State license is suspended or revoked, the DEA may revoke the federal registration.
15-Day Reconsideration Opportunity
The Order allows James Orrington II to file a properly supported motion for reconsideration of the findings of fact within fifteen calendar days of the date of the Order. Any such motion and responses must be filed and served by email to the other party and to the DEA Office of the Administrator at [email protected].
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-16665, Exempt Chemical Preparations Under the Controlled Substances Act
The applications for exempt chemical preparations received by the Drug Enforcement Administration between March 1, 2026, and June 30, 2026, as listed below, were accepted for filing and have been approved or denied as indicated. This publication addresses preparations through June 30, 2026, that were not included in previous Federal Register notices, and it does not affect preparations that have been previously published.
2026-16413, Schedules of Controlled Substances: Temporary Placement of O-Desmethyltramadol in Schedule I
The Drug Enforcement Administration issues this temporary order to schedule O-desmethyltramadol (other names: O-DSMT; desmetramadol; 3-[(1R,2R)-2-[(dimethylamino)methyl]-1- hydroxycyclohexyl]phenol), including its isomers, esters, ethers, salts, and salts of isomers, esters and ethers, in schedule I of the Controlled Substances Act. DEA bases this action on a finding that placing O-DSMT in schedule I is necessary to avoid an imminent hazard to public safety. This order imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle O-DSMT.
2026-16375, Schedules of Controlled Substances: Rescheduling of Suvorexant, Lemborexant, and Daridorexant From Schedule IV Into Schedule V
The Drug Enforcement Administration proposes to transfer suvorexant ([(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4- diazepan-1-yl]-[5-methyl-2-(triazol-2-yl)phenyl]methanone), lemborexant ((1R,2S)-2-[(2,4-dimethylpyrimidin-5-yl)oxymethyl]-2-(3-fluorophenyl)- N-(5-fluoropyridin-2-yl)cyclopropane-1-carboxamide), and daridorexant ([(2S)-2-(5-chloro-4-methyl-1H-benzimidazol-2-yl)-2-methylpyrrolidin-1- yl]-[5-methoxy-2-(triazol-2-yl)phenyl]methanone) from schedule IV to schedule V of the Controlled Substances Act. If finalized, this action would impose the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule V controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle suvorexant, lemborexant, and daridorexant.
2026-15624, Amendment to 3,4-MDP-2-P Methyl Glycidic Acid, a List I Chemical
The Drug Enforcement Administration is proposing to modify the listing of the list I chemical 3,4-MDP-2-P methyl glycidic acid (also known as PMK glycidic acid) to include esters of 3,4-MDP-2-P methyl glycidic acid, not listed elsewhere in the Controlled Substances Act (CSA), as list I chemicals under the CSA. The current listing of 3,4- MDP-2-P methyl glycidic acid includes its salts, optical and geometric isomers, and salts of isomers. DEA proposes the new listing to read as follows: 3,4-MDP-2-P methyl glycidic acid (PMK glycidic acid) and its esters, not listed elsewhere in the CSA, its optical and geometric isomers, its salts, salts of its optical and geometric isomers, salts of its esters, not listed elsewhere in the CSA, and any combination thereof, whenever the existence of such is possible.
Previous / Next Documents
Previous: 2025-19596, United States Department of Transportation Advisory Board; Public Meeting
Heads up! The Department of Transportation canceled the Advisory Board public meeting that was set for October 22, 2025. This affects anyone planning to join or follow the meeting, but no new dates or costs were announced yet. Stay tuned for updates so you don’t miss out on future DOT news and decisions!
Next: 2025-19598, Abolghasem Rezaei, M.D.; Decision and Order
Dr. Abolghasem Rezaei from Oklahoma lost his DEA registration because he no longer has the state permission to handle controlled substances. Since he didn’t ask for a hearing, the DEA canceled his registration by default, meaning he can’t legally prescribe or manage these drugs anymore. This change is effective immediately and impacts Dr. Rezaei’s ability to work with controlled substances.